Fundraising FoxPredictive Oncology
Pittsburgh, US · Delaware corporation · 2 known investors
Find your way into Predictive Oncology
Sign up to see every warm intro you have to Predictive Oncology
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Predictive Oncology team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Predictive Oncology develops drug discovery solutions for biopharma companies that combine artificial intelligence with a proprietary biobank of over 150,000 tumor samples to accelerate oncology drug development and improve therapeutic outcomes for cancer patients.
Founders & leadership
RV
Raymond VennareExecutiveRaymond Vennare is an executive and board director with over three decades of experience in biotechnology, including roles building and managing companies for institutional investors and research institutions. He has worked in company creation, technology commercialization, and business development.
CI
Carl I SchwartzExecutive
JK
Joshua KornbergExecutive
Board
Investors · 2
Bain Capital Ventureslisted by Bain Capital VenturesBoston · $1M – $100M
How we know: baincapitalventures.com · Not right? Tell us
Yorkville AdvisorsreportedMountainside
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$275.9M disclosed across 15 rounds · 2014–2025
▶$50.8MraisedOct 2025 · 29 investors · OtherRule 506(b)
▶$50.8MraisedOct 2025 · 29 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Matthew HawrylukDirector
- Chuck NuzumDirector
- Josh BlacherExecutive Officer
- Shawn MatthewsDirector
- Veena RaoDirector
- Gregory S. St. Clair, Sr.Director
- Raymond F. VennareExecutive Officer, Director
- Thomas L. McLaughlinExecutive Officer
- Dan HadleyDirector
- Offering amount
- $50.8M
- Amount sold
- $50.8M
- Sales commissions
- $2.5M
- Placement agents
- H. C. Wainwright & Co., LLC
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$173.3MraisedOct 2025 · 20 investors · OtherRule 506(b)
▶$173.3MraisedOct 2025 · 20 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Chuck NuzumDirector
- Veena RaoDirector
- Dan HadleyDirector
- Gregory S. St. Clair, Sr.Director
- Matthew HawrylukDirector
- Raymond F. VennareExecutive Officer, Director
- Josh BlacherExecutive Officer
- Thomas L. McLaughlinExecutive Officer
- Shawn MatthewsDirector
- Offering amount
- $173.3M
- Amount sold
- $173.3M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$413.1KraisedSep 2025 · 1 investors · BiotechnologyRule 506(b)
▶$413.1KraisedSep 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nancy Chung-WelchDirector
- Dan HadleyDirector
- Raymond F. BennareExecutive Officer, Director
- Chuck NuzumDirector
- Josh BlacherExecutive Officer
- Veena RaoDirector
- Matthew HawrylukDirector
- Gregory S. St. Clair, Sr.Director
- Offering amount
- $413.1K
- Amount sold
- $413.1K
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedAug 2024 · 8 investors · BiotechnologyRule 506(b)
▶$2.2MraisedAug 2024 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Veena RaoDirector
- Chuck NuzumDirector
- Matthew HawrylukDirector
- Josh BlacherExecutive Officer
- Gregory S. St. Clair, Sr.Director
- Dan HadleyDirector
- Raymond VennareExecutive Officer, Director
- Nancy Chung-WelchDirector
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- Sales commissions
- $262.8K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedJun 2022 · 4 investors · BiotechnologyRule 506(b)
▶$2.3MraisedJun 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- J Melville EngleExecutive Officer, Director
- Christina JenkinsDirector
- Nancy Chung-WelchDirector
- Daniel E HandleyDirector
- Bob MyersExecutive Officer
- Raymond VennareDirector
- Chuck NuzumDirector
- Gregory St. ClairDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- Sales commissions
- $195.7K
- Placement agents
- H.C. Wainwright & Co. LLC
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17.6MraisedMar 2021 · 19 investors · BiotechnologyRule 506(b)
▶$17.6MraisedMar 2021 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carl I SchwartzExecutive Officer, Director
- Bob MyersExecutive Officer
- J Melville EngleDirector
- Nancy Chung-WelchDirector
- Daniel E HandleyDirector
- Gregory S St. Clair Sr.Director
- Chuck NuzumDirector
- Richard L GabrielDirector
- Offering amount
- $17.6M
- Amount sold
- $17.6M
- Sales commissions
- $1.6M
- Placement agents
- H.C. Wainwright & Co. LLC
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.8MraisedMar 2021 · 10 investors · BiotechnologyRule 506(b)
▶$16.8MraisedMar 2021 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard L GabrielDirector
- Daniel E HandleyDirector
- Gregory S St. Clair Sr.Director
- Chuck NuzumDirector
- Nancy Chung-WelchDirector
- Carl I SchwartzExecutive Officer, Director
- Bob MyersExecutive Officer
- J Melville EngleDirector
- Offering amount
- $16.8M
- Amount sold
- $16.8M
- Sales commissions
- $951K
- Placement agents
- H.C. Wainwright & Co. LLC
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.8MraisedJul 2020 · 18 investors · BiotechnologyRule 506(b)
▶$1.8MraisedJul 2020 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew P RedingDirector
- Daniel E HandleyDirector
- J Melville EngleDirector
- Richard L GabrielDirector
- Carl I SchwartzExecutive Officer, Director, Promoter
- Bob MyersExecutive Officer
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Acquisitions · 1
Early investors' stakes continue via these dealszPREDICTA
zPREDICTA manufactures three-dimensional tissue culture models derived from patient samples that recreate human organ microenvironments for drug testing. Pharmaceutical companies and researchers use the models to evaluate cancer drug candidates and predict clinical efficacy before human trials.
Frequently asked questions
- What does Predictive Oncology do?
- Predictive Oncology develops drug discovery solutions for biopharma companies that combine artificial intelligence with a proprietary biobank of over 150,000 tumor samples to accelerate oncology drug development and improve therapeutic outcomes for cancer patients.
- Who are Predictive Oncology's investors?
- Predictive Oncology's investors include Bain Capital Ventures, Yorkville Advisors.
- How much funding has Predictive Oncology raised?
- Predictive Oncology has disclosed $275.9M raised across 15 rounds.
- Where is Predictive Oncology headquartered?
- Predictive Oncology is headquartered in Pittsburgh, US.